Navigation Links
CV Therapeutics Reports 2008 First Quarter Financial Results
Date:4/25/2008

PALO ALTO, Calif., April 25 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the first quarter ended March 31, 2008.

For the quarter ended March 31, 2008, the Company reported a net loss of $31.9 million, or $0.53 per share. This compares to a net loss of $34.1 million, or $0.57 per share, for the prior quarter ended December 31, 2007 and $55.1 million, or $0.93 per share, for the same quarter in 2007.

For the quarter ended March 31, 2008, the Company recorded total revenues of $22.8 million which consisted of $22.0 million of net product sales of Ranexa(R) (ranolazine extended-release tablets) and $0.8 million of collaborative research revenue. The $22.0 million of net product sales of Ranexa in the quarter ended March 31, 2008 represents an increase of five percent compared to the $20.9 million of net product sales of Ranexa(R) recorded in the prior quarter ended December 31, 2007 and an increase of 83 percent compared to the $12.0 million of net product sales in the same quarter of the prior year. The first quarter 2008 collaborative research revenue includes revenue primarily related to the reimbursement of certain regadenoson development costs from our collaborative partner.

Costs and expenses were $53.1 million for the quarter ended March 31, 2008. This compares to total costs and expenses of $55.8 million for the prior quarter ended December 31, 2007 and $71.2 million for the same quarter in 2007. The decrease of total costs and expenses in the quarter ended March 31, 2008 compared to the prior quarter ended December 31, 2007 was primarily due to lower research and development costs associated with various development projects, lower Ranexa marketing and sales
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Laboratory (IL) today announced that their Strategic Alliance ... June 22, 2012, after more than twenty successful ... direct sales, service, support and marketing to end-user ... own Hemostasis product line, including the HemosIL® line ...
... Pharmaceuticals today announced that the United States Patent and ... entitled, "Antibodies specific to heterodimers of Bcl-2 family and ... method for extending Eutropics, BH3 profiling technology, which is ... technology assesses the ability of a key part of ...
... 2012  Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... an update on the progress of Sangamo,s ZFP Therapeutic® development ... the following conferences: , The 11th Annual JMP ... PT (6:00 pm ET), on Monday, May 14, 2012. ...
Cached Biology Technology:Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America 2Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America 3Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method 2Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences 2
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... of a gene that optimizes their brain's thinking circuitry, ... severe mental illness marked by impaired thinking, scientists at ... Mental Health (NIMH) have discovered. The seeming paradox ... of variation in the human gene for a brain ...
... of epicatechin, a compound found in cocoa, are so striking ... importance to public health, reports Marina Murphy in Chemistry & ... medicine at Harvard Medical School, told C&I that epicatechin is ... , Hollenberg has spent years studying the benefits of cocoa ...
... Researchers from Université Laval’s Faculty of Medicine have ... antiwrinkle products causes a pathological reaction in skin ... present their conclusions about the mode of action ... the British Journal of Dermatology. , DMAE (2-dimethylaminoethanol) ...
Cached Biology News:Common gene version optimizes thinking -- but with a possible downside 2Cocoa 'vitamin' health benefits could outshine penicillin 2Anti-wrinkle compound causes pathological reaction in skin cells 2
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
DONOR BOVINE SERUM AND PLASMA...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
Biology Products: